Literature DB >> 30407793

5 S,15 S-Dihydroperoxyeicosatetraenoic Acid (5,15-diHpETE) as a Lipoxin Intermediate: Reactivity and Kinetics with Human Leukocyte 5-Lipoxygenase, Platelet 12-Lipoxygenase, and Reticulocyte 15-Lipoxygenase-1.

Abigail R Green1, Cody Freedman1, Jennyfer Tena1, Benjamin E Tourdot2, Benjamin Liu1, Michael Holinstat2, Theodore R Holman1.   

Abstract

The reaction of 5 S,15 S-dihydroperoxyeicosatetraenoic acid (5,15-diHpETE) with human 5-lipoxygenase (LOX), human platelet 12-LOX, and human reticulocyte 15-LOX-1 was investigated to determine the reactivity and relative rates of producing lipoxins (LXs). 5-LOX does not react with 5,15-diHpETE, although it can produce LXA4 when 15-HpETE is the substrate. In contrast, both 12-LOX and 15-LOX-1 react with 5,15-diHpETE, forming specifically LXB4. For 12-LOX and 5,15-diHpETE, the kinetic parameters are kcat = 0.17 s-1 and kcat/ KM = 0.011 μM-1 s-1 [106- and 1600-fold lower than those for 12-LOX oxygenation of arachidonic acid (AA), respectively]. On the other hand, for 15-LOX-1 the equivalent parameters are kcat = 4.6 s-1 and kcat/ KM = 0.21 μM-1 s-1 (3-fold higher and similar to those for 12-HpETE formation by 15-LOX-1 from AA, respectively). This contrasts with the complete lack of reaction of 15-LOX-2 with 5,15-diHpETE [Green, A. R., et al. (2016) Biochemistry 55, 2832-2840]. Our data indicate that 12-LOX is markedly inferior to 15-LOX-1 in catalyzing the production of LXB4 from 5,15-diHpETE. Platelet aggregation was inhibited by the addition of 5,15-diHpETE, with an IC50 of 1.3 μM; however, LXB4 did not significantly inhibit collagen-mediated platelet activation up to 10 μM. In summary, LXB4 is the primary product of 12-LOX and 15-LOX-1 catalysis, if 5,15-diHpETE is the substrate, with 15-LOX-1 being 20-fold more efficient than 12-LOX. LXA4 is the primary product with 5-LOX but only if 15-HpETE is the substrate. Approximately equal proportions of LXA4 and LXB4 are produced by 12-LOX but only if LTA4 is the substrate, as described previously [Sheppard, K. A., et al. (1992) Biochim. Biophys. Acta 1133, 223-234].

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30407793      PMCID: PMC7270142          DOI: 10.1021/acs.biochem.8b00889

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  Rethinking fundamentals of enzyme action.

Authors:  D B Northrop
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1999

2.  Requirement of monohydroperoxy fatty acids for the oxygenation of 15LS-HETE by reticulocyte lipoxygenase.

Authors:  H Kühn; R Wiesner; H Stender; T Schewe; V Z Lankin; A Nekrasov; S M Rapoport
Journal:  FEBS Lett       Date:  1986-07-28       Impact factor: 4.124

3.  Kinetic investigations of the rate-limiting step in human 12- and 15-lipoxygenase.

Authors:  Erika N Segraves; Theodore R Holman
Journal:  Biochemistry       Date:  2003-05-13       Impact factor: 3.162

4.  Lipoxin synthase activity of human platelet 12-lipoxygenase.

Authors:  M Romano; X S Chen; Y Takahashi; S Yamamoto; C D Funk; C N Serhan
Journal:  Biochem J       Date:  1993-11-15       Impact factor: 3.857

5.  Investigations of human platelet-type 12-lipoxygenase: role of lipoxygenase products in platelet activation.

Authors:  Kenneth N Ikei; Jennifer Yeung; Patrick L Apopa; Jesús Ceja; Joanne Vesci; Theodore R Holman; Michael Holinstat
Journal:  J Lipid Res       Date:  2012-09-13       Impact factor: 5.922

6.  Kinetic and structural investigations of the allosteric site in human epithelial 15-lipoxygenase-2.

Authors:  Aaron T Wecksler; Victor Kenyon; Natalie K Garcia; Joshua D Deschamps; Wilfred A van der Donk; Theodore R Holman
Journal:  Biochemistry       Date:  2009-09-15       Impact factor: 3.162

7.  Strict Regiospecificity of Human Epithelial 15-Lipoxygenase-2 Delineates Its Transcellular Synthesis Potential.

Authors:  Abigail R Green; Shannon Barbour; Thomas Horn; Jose Carlos; Jevgenij A Raskatov; Theodore R Holman
Journal:  Biochemistry       Date:  2016-05-13       Impact factor: 3.162

8.  Lipoxin generation by human megakaryocyte-induced 12-lipoxygenase.

Authors:  K A Sheppard; S M Greenberg; C D Funk; M Romano; C N Serhan
Journal:  Biochim Biophys Acta       Date:  1992-01-13

9.  Lipoxin synthesis by arachidonate 12-lipoxygenase purified from porcine leukocytes.

Authors:  N Ueda; C Yokoyama; S Yamamoto; B J Fitzsimmons; J Rokach; J A Oates; A R Brash
Journal:  Biochem Biophys Res Commun       Date:  1987-12-31       Impact factor: 3.575

10.  Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.

Authors:  J Clària; C N Serhan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-10       Impact factor: 11.205

View more
  9 in total

1.  Biosynthesis of the Maresin Intermediate, 13S,14S-Epoxy-DHA, by Human 15-Lipoxygenase and 12-Lipoxygenase and Its Regulation through Negative Allosteric Modulators.

Authors:  Cody Freedman; Adrianne Tran; Benjamin E Tourdot; Chakrapani Kalyanaraman; Steve Perry; Michael Holinstat; Matthew P Jacobson; Theodore R Holman
Journal:  Biochemistry       Date:  2020-05-07       Impact factor: 3.162

Review 2.  Achieving Life through Death: Redox Biology of Lipid Peroxidation in Ferroptosis.

Authors:  Hülya Bayır; Tamil S Anthonymuthu; Yulia Y Tyurina; Sarju J Patel; Andrew A Amoscato; Andrew M Lamade; Qin Yang; Georgy K Vladimirov; Caroline C Philpott; Valerian E Kagan
Journal:  Cell Chem Biol       Date:  2020-04-09       Impact factor: 8.116

3.  15-Lipoxygenase-1 biosynthesis of 7S,14S-diHDHA implicates 15-lipoxygenase-2 in biosynthesis of resolvin D5.

Authors:  Steven C Perry; Chakrapani Kalyanaraman; Benjamin E Tourdot; William S Conrad; Oluwayomi Akinkugbe; John Cody Freedman; Michael Holinstat; Matthew P Jacobson; Theodore R Holman
Journal:  J Lipid Res       Date:  2020-05-13       Impact factor: 5.922

Review 4.  Redox (phospho)lipidomics of signaling in inflammation and programmed cell death.

Authors:  Yulia Y Tyurina; Claudette M St Croix; Simon C Watkins; Alan M Watson; Michael W Epperly; Tamil S Anthonymuthu; Elena R Kisin; Irina I Vlasova; Olga Krysko; Dmitri V Krysko; Alexandr A Kapralov; Haider H Dar; Vladimir A Tyurin; Andrew A Amoscato; Elena N Popova; Sergey B Bolevich; Peter S Timashev; John A Kellum; Sally E Wenzel; Rama K Mallampalli; Joel S Greenberger; Hulya Bayir; Anna A Shvedova; Valerian E Kagan
Journal:  J Leukoc Biol       Date:  2019-05-09       Impact factor: 4.962

5.  Role of Human 15-Lipoxygenase-2 in the Biosynthesis of the Lipoxin Intermediate, 5S,15S-diHpETE, Implicated with the Altered Positional Specificity of Human 15-Lipoxygenase-1.

Authors:  Steven C Perry; Thomas Horn; Benjamin E Tourdot; Adriana Yamaguchi; Chakrapani Kalyanaraman; William S Conrad; Oluwayomi Akinkugbe; Michael Holinstat; Matthew P Jacobson; Theodore R Holman
Journal:  Biochemistry       Date:  2020-10-13       Impact factor: 3.162

Review 6.  Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.

Authors:  Bei Wang; Lujin Wu; Jing Chen; Lingli Dong; Chen Chen; Zheng Wen; Jiong Hu; Ingrid Fleming; Dao Wen Wang
Journal:  Signal Transduct Target Ther       Date:  2021-02-26

7.  In Vitro Biosynthetic Pathway Investigations of Neuroprotectin D1 (NPD1) and Protectin DX (PDX) by Human 12-Lipoxygenase, 15-Lipoxygenase-1, and 15-Lipoxygenase-2.

Authors:  Wan-Chen Tsai; Chakrapani Kalyanaraman; Adriana Yamaguchi; Michael Holinstat; Matthew P Jacobson; Theodore R Holman
Journal:  Biochemistry       Date:  2021-05-24       Impact factor: 3.162

8.  Eicosapentaenoic acid's metabolism of 15-LOX-1 promotes the expression of miR-101 thus inhibits Cox2 pathway in colon cancer.

Authors:  Yi Cai; Jie Liu; Shao-Kang Cai; Er-Ya Miao; Cheng-Qian Jia; Yong-Zhi Fan; Ying-Bo Li
Journal:  Onco Targets Ther       Date:  2020-06-15       Impact factor: 4.147

Review 9.  Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?

Authors:  Nils Helge Schebb; Hartmut Kühn; Astrid S Kahnt; Katharina M Rund; Valerie B O'Donnell; Nicolas Flamand; Marc Peters-Golden; Per-Johan Jakobsson; Karsten H Weylandt; Nadine Rohwer; Robert C Murphy; Gerd Geisslinger; Garret A FitzGerald; Julien Hanson; Claes Dahlgren; Mohamad Wessam Alnouri; Stefan Offermanns; Dieter Steinhilber
Journal:  Front Pharmacol       Date:  2022-03-02       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.